TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Treatment of Patients With Pulmonary Embolism Based on Pro-BNP Levels
Brief Summary: The aim of this study is to investigate the safety of treatment of pulmonary embolism in an outpatient setting based on normal pro-BNP levels. The mortality rate and the incidence of hemodynamic instability as well as major bleeding and recurrent venous thromboembolism (VTE) in the outpatient group will be studied.


Options:
A: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment
B: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A
C: Arm Label: Outpatient treatment; Type: EXPERIMENTAL; Interventions: Other: Outpatient care (vs traditional inpatient care) | Arm Label: Inpatient care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outpatient care (vs traditional inpatient care); Assigned to Arm(s): Outpatient treatment
D: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Treatment of Patients With Pulmonary Embolism Based on Pro-BNP Levels
Brief Summary: The aim of this study is to investigate the safety of treatment of pulmonary embolism in an outpatient setting based on normal pro-BNP levels. The mortality rate and the incidence of hemodynamic instability as well as major bleeding and recurrent venous thromboembolism (VTE) in the outpatient group will be studied.


Options:
A: Intervention Type: PROCEDURE; Name: home treatment; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: treatment at home; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Integration of electronic clinical decision support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integration of electronic clinical decision support; Assigned to Arm(s): Intervention
D: Arm Label: Outpatient Treatment; Type: N/A; Interventions: Other: Outpatient Treatment of Pulmonary Embolism | Intervention Type: OTHER; Name: Outpatient Treatment of Pulmonary Embolism; Assigned to Arm(s): Outpatient Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis.
Brief Summary: This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are latently infected with M.tb. A single vaccination with MVA85A, when administeredat a dose of 5 x 107pfu intradermally, is safe in both mycobacterially naïve individuals and those previously vaccinated with BCG. We will use the same vaccination regime in this study. Subjects will be defined as being latently infected if they have a positive elispot response to ESAT6 or CFP10. Subjects will be identified from TB contact clinics.


Options:
A: Intervention Type: BIOLOGICAL; Name: MVA 85A; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: MVA85A/AERAS-485; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): MVA85A/AERAS-485 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Intervention Type: BIOLOGICAL; Name: BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group A, Group C | Intervention Type: BIOLOGICAL; Name: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group B, Group D
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): Group 1, Group 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Longitudinal Study on Health and Diet (Etude Longitudinale Prospective Alimentation et Santé)
Brief Summary: We hypothesize that Family Dietary Coaching for one school year will allow a nutritional shift towards following recommendations and improve health indicators in free-living children and adults.


Options:
A: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A
B: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
C: Intervention Type: BEHAVIORAL; Name: Fat and carbohydrate controlled diet; Assigned to Arm(s): N/A
D: Arm Label: A, Observational; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Longitudinal Study on Health and Diet (Etude Longitudinale Prospective Alimentation et Santé)
Brief Summary: We hypothesize that Family Dietary Coaching for one school year will allow a nutritional shift towards following recommendations and improve health indicators in free-living children and adults.


Options:
A: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
B: Intervention Type: BEHAVIORAL; Name: Fat and carbohydrate controlled diet; Assigned to Arm(s): N/A
C: Arm Label: A, Observational; Type: N/A; Interventions: N/A
D: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.
Brief Summary: The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
B: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
D: Intervention Type: DRUG; Name: enoxaparin sodium; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study
Brief Summary: The purpose of this study is to assess efficacy and safety of optional vena cava filter implanted 3 months in prevention of recurrent pulmonary embolism in patients presenting with acute pulmonary embolism associated with thrombotic risk factors


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: ALN optional filter | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ALN optional filter; Assigned to Arm(s): 1
B: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
C: Arm Label: pulmonary embolism; Type: N/A; Interventions: N/A
D: Arm Label: EkoSonic® Endovascular System; Type: EXPERIMENTAL; Interventions: Drug: recombinant tissue plasminogen activator, Device: EKOS EkoSonic Endovascular System | Intervention Type: DRUG; Name: recombinant tissue plasminogen activator; Assigned to Arm(s): EkoSonic® Endovascular System | Intervention Type: DEVICE; Name: EKOS EkoSonic Endovascular System; Assigned to Arm(s): EkoSonic® Endovascular System

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hypothermia After In-hospital Cardiac Arrest
Brief Summary: ILCOR Recommendations "On the basis of the published evidence to date, the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR) made the following recommendations in October 2002: Unconscious adult patients with spontaneous circulation after out-of-hospital cardiac arrest should be cooled to 32°C to 34°C for 12 to 24 hours when the initial rhythm was ventricular fibrillation (VF).Such cooling may also be beneficial for other rhythms or in-hospital cardiac arrest" (Circulation. 2003;108:118-121). This study ist to investigate the efficacy of mild therapeutic hypothermia on mortality and neurological outcome in patients after in-hospital cardiac arrest.


Options:
A: Arm Label: control treatment; Type: NO_INTERVENTION; Interventions: Other: Rapid infusion of 2 liters of 4oC normal saline, Drug: Rapid infusion of cold normal saline | Intervention Type: OTHER; Name: Rapid infusion of 2 liters of 4oC normal saline; Assigned to Arm(s): control treatment | Intervention Type: DRUG; Name: Rapid infusion of cold normal saline; Assigned to Arm(s): control treatment
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hypothermia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mild therapeutic hypothermia | Intervention Type: PROCEDURE; Name: Mild therapeutic hypothermia; Assigned to Arm(s): Hypothermia
C: Arm Label: Normothermia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard care with early treatment of fever | Arm Label: Hypothermia; Type: EXPERIMENTAL; Interventions: Procedure: Targeted temperature management to 33°C | Intervention Type: PROCEDURE; Name: Targeted temperature management to 33°C; Assigned to Arm(s): Hypothermia | Intervention Type: PROCEDURE; Name: Standard care with early treatment of fever; Assigned to Arm(s): Normothermia
D: Arm Label: Target Temperature 33°C; Type: EXPERIMENTAL; Interventions: Procedure: Target Temperature 33°C | Arm Label: Target Temperature 36°C; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Target temperature 36°C | Intervention Type: PROCEDURE; Name: Target temperature 36°C; Assigned to Arm(s): Target Temperature 36°C | Intervention Type: PROCEDURE; Name: Target Temperature 33°C; Assigned to Arm(s): Target Temperature 33°C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Effectiveness of BI Given to Injured MVC ED Patients Who Use Alcohol Harmfully and Hazardously
Brief Summary: The purpose of this study is to determine if a brief counseling intervention, delivered by telephone, is more effective than standard ED care, to reduce future alcohol related injuries and alcohol related negative consequences, among patients treated in the ED for injuries from an MVC and other injury mechanisms.


Options:
A: Arm Label: 1 Brief Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention | Arm Label: 2) Booster; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention plus booster | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention; Assigned to Arm(s): 1 Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention plus booster; Assigned to Arm(s): 2) Booster
B: Arm Label: EARLY; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing plus feedback | Arm Label: Video Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video | Arm Label: Informational Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Informational Brochure | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing plus feedback; Assigned to Arm(s): EARLY | Intervention Type: BEHAVIORAL; Name: Video; Assigned to Arm(s): Video Information | Intervention Type: BEHAVIORAL; Name: Informational Brochure; Assigned to Arm(s): Informational Brochure
C: Intervention Type: BEHAVIORAL; Name: Brief Telephone Counseling for risky aclohol use; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Brief intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Brief intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study was designed to compare the difference of using atropine eyedrops alone from atropine combined with the stimulation of auricular acupoints therapy in reducing myopia progression.


Options:
A: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
B: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation
C: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study was designed to compare the difference of using atropine eyedrops alone from atropine combined with the stimulation of auricular acupoints therapy in reducing myopia progression.


Options:
A: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
B: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)
C: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
D: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study was designed to compare the difference of using atropine eyedrops alone from atropine combined with the stimulation of auricular acupoints therapy in reducing myopia progression.


Options:
A: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
B: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation
C: Arm Label: Test Lens A; Type: EXPERIMENTAL; Interventions: Device: Soft Contact Test Lens A | Arm Label: Test Lens C; Type: EXPERIMENTAL; Interventions: Device: Soft Contact Test Lens C | Intervention Type: DEVICE; Name: Soft Contact Test Lens A; Assigned to Arm(s): Test Lens A | Intervention Type: DEVICE; Name: Soft Contact Test Lens C; Assigned to Arm(s): Test Lens C
D: Arm Label: orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: orthokeratology lenses | Arm Label: single-vision spectacle lenses; Type: OTHER; Interventions: Device: single-vision spectacle lenses | Intervention Type: DEVICE; Name: orthokeratology lenses; Assigned to Arm(s): orthokeratology lenses | Intervention Type: DEVICE; Name: single-vision spectacle lenses; Assigned to Arm(s): single-vision spectacle lenses

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
Brief Summary: The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.


Options:
A: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
B: Arm Label: Everolimus (RAD001); Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus (RAD001)
C: Intervention Type: DRUG; Name: Rapamycin, sirolimus; Assigned to Arm(s): N/A
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
Brief Summary: The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.


Options:
A: Intervention Type: DRUG; Name: Rapamycin, sirolimus; Assigned to Arm(s): N/A
B: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm
C: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin

Answer: A